Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : AM-Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : KBI will conduct manufacturing and validation in its existing facilities. AM-Pharma and KBI Biopharma began collaborating on the recAP program in 2011 when KBI performed initial process development and cGMP manufacturing for early clinical use.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : AM-Pharma
Deal Size : Undisclosed
Deal Type : Agreement